Bigdrive99... Besides institutional investors not knowing beans about the science (as Bag8ger just said), most institutional investors exclude "risky" penny stocks for their portfolios as a simple matter of institution policy and it has nothing at all to do with DNAP, so it's not a concern.
DNAP's technology and expertise IS cutting edge and world class...proven, validated, peer-reviewed, with revenue generating successful "first of a kind" consumer and forensics products.
DNAP is specializing in state of the art population genomics which IS the leading edge of the molecular genetics and the human genome revolution. Population genomics IS the key to the mapping and discovery of important ancestry and disease SNP's.
Now, DNAP is transforming itself into a pharmacogenomics company as the next step.
Besides, right now, it's more important that people like Moffitt, Dr. Paul McKeigue, and Biofrontera know who DNAP is...and know what DNAP has...
Institutional investors will come into the picture as we work towards NASDAQ.
In any case, it's just your humble opinion and it's no better than any other...
Just as this is IMHO as well.
God's Speed To DNAP and To All DNAP Investors,
Robert
Market Data 
Markets 
AI
